A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma

Pathology International

Volumn 62, Issue 4, 2012, Pages 226-231

  Enomoto, Yasunori ^a   Kasai, Takahiko ^a   Takeda, Maiko ^a   Takano, Masato ^a   Morita, Kouhei ^a   Kadota, Eiji ^c   Iizuka, Norishige ^c   Maruyama, Hiroshi ^d   Haratake, Joji ^e   Kojima, Yu ^b   Ikeda, Naoya ^b   Nonomura, Akitaka ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c Kishiwada City Hospital   (Japan)

^d HOSHIGAOKA KOSEINENKIN HOSPITAL   (Japan)

^e Saiseikai Yahata General Hospital   (Japan)

Author keywords

Epidermal growth factor receptor; FISH; Gene copy number gain; Immunohistochemistry; Malignant mesothelioma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PERITONEUM MESOTHELIOMA; PHENOTYPE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; DNA, NEOPLASM; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84859008835     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2011.02778.x     Document Type: Article

References (26)

1. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345: 535-9.
2. Peto J, Decarli A, La VC, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666-72.
3. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145: 211-8.
4. Pass HI, Kranda K, Temeck BK, Feuerstein I, Steinberg SM. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors. Ann Surg Oncol 1997; 4: 215-22.
5. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A LungCancer Study Group trial. J Thorac Cardiovasc Surg 1991; 102: 1-9.
6. Vogelzang NJ, Rusthoven JJ, Symanowski J etal. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44.
7. Takeda M, Kasai T, Enomoto Y etal. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int 2010; 60: 395-9.
8. Rena O, Boldorini LR, Gaudino E, Casadio C. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations. J Surg Oncol 2011; 1; 104(6): 701-5.
9. Hirsch FR, Varella-Garcia M, Bunn PA etal. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-807.
10. Martin V, Mazzucchelli L, Frattini M. An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J Clin Pathol 2009; 62: 314-24.
11. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002; 29: 2-17.
12. Gee GV, Stanifer ML, Christensen BC etal. SV40 associated miRNAs are not detectable in mesotheliomas. Br J Cancer 2010; 103: 885-8.
13. López-Ríos F, Illei PB, Rusch V, Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 2004; 364: 1157-66.
14. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 2081-90.
15. Hesdorffer ME, Chabot J, DeRosa C, Taub R. Peritoneal mesothelioma. Curr Treat Options Oncol 2008; 9: 180-90.
16. Okuda K, Sasaki H, Dumontet C etal. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 2008; 134: 1105-11.
17. Trupiano JK, Geisinger KR, Willingham MC etal. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004; 17: 476-81.
18. Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R, Chatterjee AK. Malignant pleural mesothelioma and epidermal growth factor receptor (EGFR). Relationship of EGFR with histology and survival using fixed paraffin-embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990; 61: 924-6.
19. Destro A, Ceresoli GL, Falleni M etal. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006; 51: 207-15.
20. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9-S15.
21. Edwards JG, Swinson DE, Jones JL, Waller DA, O'Byrne KJ. EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006; 54: 399-3407.
22. Cappuzzo F, Hirsch FR, Rossi E etal. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643-55.
23. Garland LL, Rankin C, Gandara DR etal. Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study. J Clin Oncol 2007; 25: 2406-13.
24. Govindan R, Kratzke RA, Herndon JE etal. Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005; 11: 2300-4.
25. Foster JM, Radhakrishna U, Govindarajan V etal. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J Surg Oncol 2010; 8: 88.
26. Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. Ann Surg Oncol 2009; 16: 152-8.